EIF and K.U.Leuven announce milestone partnership
The Katholieke Universiteit Leuven (K.U.Leuven) and the European Investment Fund (EIF) have entered a partnership agreement to create a Centre for drug design and Discovery ("CD3"). CD3 will build upon research carried out in the biomedical field at the K.U.Leuven in order to discover novel therapeutic compounds directed against biological targets which are investigated within the research groups. In this way, the parties intend to further bridge the gap between academic biomedical research and the needs of the applied industrial research. This initiative will boost translational research and technology transfer in the life sciences field.
CD3 will source projects from the various research groups in life sciences of the K.U.Leuven, and in second instance from external partners such as other research institutions. It will seek to collaborate with and/or license results to the pharmaceutical and biotech industry.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.